Human Immunology Core

项目概要-人类免疫学核心 艾布拉姆森癌症中心（ACC）的人类免疫学核心（HIC）是第一个也是最活跃的 免疫监测核心设施HIC的使命是提供湿台专业知识， 使用经验证的免疫学检测将最新技术纳入I/II期临床试验， 同时还为研究人员提供专家科学和技术咨询， research. HIC提供的服务包括科学咨询、样品处理、活细胞保存 细胞和分子免疫学中的标准、定制和新型分析，数据分析， 人类细胞产品。HIC可以在试点研究的基础上或在良好的标准上进行研究 实验室实践，如需要。HIC的科学总监是Eline T博士。Luning Prak，教授 病理学和实验室医学，他是一名临床病理学家，拥有20年的临床实验室经验， 在B淋巴细胞生物学和免疫谱方面的研究专长。在她的领导下，HIC 大幅扩大了样本的登记和处理服务， 针对人类免疫细胞亚群的免疫表型板，并开发了一套复杂的抗体 和T细胞受体谱分析，包括高复杂性免疫数据分析能力。 核心技术总监赵玲博士在肿瘤基因组学和单细胞检测方面拥有专业知识， 超灵敏蛋白质检测分析的开发和实施。副教授 博士詹姆斯·莱利，微生物学副教授，具有淋巴细胞分离，调节T细胞 癌症和慢性病毒感染的生物学和T细胞反应。莱利博士负责细胞产品服务。 在最近的一次调查中，173名调查者中有74名（43%）使用了共享资源。 报告所述期间（2018年1月7日至2019年6月30日）。来自七个项目的研究人员使用抗癌疗法， 血液肿瘤学、免疫生物学、儿科肿瘤学、放射生物学和成像学、烟草和 环境致癌作用与肿瘤生物学。自上次更新以来，HIC为更多的 290多个研究项目，包括61个ACC临床试验，并提供了500多项科学研究， 咨询，包括协助74份赠款申请。HIC提供的服务支持多个 高影响力的研究;例如，在HIC开发的方法也被用来创建一个地图集， 使用来自器官供体的组织，在人体内大规模扩增B细胞克隆（Meng等，纳特生物技术公司， 2017年）。HIC拥有一支高技能的科学家团队，他们帮助ACC调查人员解决实验性的问题。 为大大小小的免疫学项目进行设计、后勤安排和实验室工作。

PROJECT SUMMARY – Human Immunology Core The Human Immunology Core (HIC) in the Abramson Cancer Center (ACC) is one of the first and most active immune monitoring core facilities in the United States. The HIC mission is to provide wet bench expertise for the incorporation of the newest technologies into Phase I/II clinical trials using validated immunology assays, while also offering expert scientific and technical consultation to investigators conducting translational research. Services provided by the HIC are scientific consultation, sample processing, viable cell preservation and storage, standard, customized and novel assays in cellular and molecular immunology, data analysis, and human cell products. The HIC can perform studies on a pilot research basis or at the standard of Good Laboratory Practices, as needed. The Scientific Director of the HIC is Dr. Eline T. Luning Prak, Professor of Pathology and Laboratory Medicine, who is a clinical pathologist with 20 years of clinical lab experience and research expertise in B lymphocyte biology and immune repertoire profiling. Under her leadership, the HIC substantially expanded its sample accessioning and processing services, created several multicolor immunophenotyping panels for human immune cell subsets, and developed a suite of sophisticated antibody and T cell receptor repertoire profiling assays, including high-complexity immune data analysis capabilities. Core Technical Director Dr. Ling Zhao has expertise in oncogenomics and single cell assays and spearheaded the development and implementation of ultrasensitive protein detection assays. Associated Faculty member Dr. James Riley, Associate Professor of Microbiology, has expertise in lymphocyte isolation, regulatory T-cell biology and T-cell responses in cancer and chronic viral infection. Dr. Riley oversees the cell products service. ACC members accounted for 74 of 173 investigators (43%) using the Shared Resource during the most recent reporting period (07/01/18-06/30/19). Investigators from seven Programs use the HIC—Cancer Therapeutics, Hematologic Malignancies, Immunobiology, Pediatric Oncology, Radiobiology and Imaging, Tobacco and Environmental Carcinogenesis, and Tumor Biology. Since the last renewal, the HIC provided support for more than 290 research projects, including 61 ACC clinical trials, and provided more than 500 scientific consultations, including assistance with 74 grant applications. Services provided by the HIC support multiple high-impact research studies; for example, methods developed in the HIC were also used to create an atlas of large expanded B-cell clones in the human body, using tissues from organ donors (Meng et al., Nat Biotech, 2017). The HIC has a highly skilled team of scientists who help ACC investigators tackle the experimental design, logistical arrangements and bench work for immunology projects large and small.